Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Correction: Trastuzumab effect...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.

[This corrects the article DOI: 10.1371/journal.pone.0234991.].

Bibliographic Details
Main Author: PLOS ONE Staff
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0241089
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1371/journal.pone.0241089

Similar Items

  • Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
    by: Anna Burguin, et al.
    Published: (2020-01-01)
  • Correction: HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers.
    by: PLOS ONE Staff
    Published: (2024-01-01)
  • Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
    by: Sibylle Loibl, et al.
    Published: (2022-09-01)
  • HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer
    by: Ansh Kapil, et al.
    Published: (2024-05-01)
  • PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
    by: Abul Azad, et al.
    Published: (2025-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs